Deeksha Vishwamitra

Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

Carolina Schinke, Cyrille Touzeau, Monique C. Minnema et al. · Journal of Clinical Oncology · 2023 · 89 citations

Medicine, Pharmacology, Pharmacotherapy +16

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos et al. · Blood Advances · 2023 · 78 citations · Full text

Life Sciences, Hematology, Immunology +17

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma

Holly Lee, Michael Durante, Sheri Skerget et al. · Blood · 2024 · 63 citations · Full text

Life Sciences, Immunology, Oncology +17

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong et al. · Blood · 2022 · 60 citations

Medicine, Oncology, Pharmacotherapy +15

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Diana Cortés‐Selva, Tatiana Perova, Sheri Skerget et al. · Blood · 2024 · 53 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17